Abstracts tagged "Late-Breaking 2021"

Abstract Number: L13 • ACR Convergence 2021
Efficacy and Safety of Subcutaneous Belimumab (BEL) and Rituximab (RTX) Sequential Therapy in Patients with Systemic Lupus Erythematosus: The Phase 3, Randomized, Placebo-Controlled BLISS-BELIEVE Study
Cynthia Aranow¹, Cornelia Allaart², Zahir Amoura³, Ian N Bruce⁴, Patricia Cagnoli⁵, Richard Furie¹, Paul Peter Tak⁶, Murray Urowitz⁷, Ronald van Vollenhoven⁸, Kenneth L Clark⁶, Mark Daniels⁹, Norma Lynn Fox¹⁰, Yun Irene Gregan¹⁰, James Groark¹¹, Robert B Henderson⁹, Mary Oldham⁹, Don Shanahan⁹, Andre van Maurik⁹, David A Roth¹⁰ and YK Onno Teng², ¹Feinstein Institutes for Medical Research, Northwell Health, Great Neck, NY, ²Leiden University Medical Center, Leiden, Netherlands, ³Centre National de reference pour le Lupus, Service de Medecine Interne 2, Institut E3M, Hopital Pitié-Salpétrière, Paris, France, ⁴NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Trust and Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵University of Michigan Medical Center, Ann Arbor, MI, ⁶GlaxoSmithKline (At the time of the author's contribution to this study), Stevenage, United Kingdom, ⁷Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁸Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁹GlaxoSmithKline, Stevenage, United Kingdom, ¹⁰GlaxoSmithKline, Collegeville, PA, ¹¹GlaxoSmithKline (At the time of the author's contribution to this study), Collegeville, PA
Background/Purpose: Disease control remains an unmet need in SLE. The rationale for sequential BEL and RTX therapy in SLE was previously published.1 This study evaluated…
Abstract Number: L14 • ACR Convergence 2021
Effect of Avacopan, a Selective C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis
David Jayne¹, Peter Merkel², Annette Bruchfeld³, Duvuru Geetha⁴, Alexandre Karras⁵, John Niles⁶ and Pirow Bekker⁷, ¹University of Cambridge, Cambridge, United Kingdom, ²University of Pennsylvania, Philadelphia, PA, ³Linköping University, Linköping, Sweden, ⁴Johns Hopkins University, Baltimore, MD, ⁵Hopital Europeen Georges Pompidou, Paris, France, ⁶Massachusetts General Hospital, Boston, MA, ⁷ChemoCentryx, Inc., San Carlos, CA
Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis is a life- or organ-threatening condition in which patients experience severe inflammation of small blood vessels; renal disease is…
Abstract Number: L15 • ACR Convergence 2021
A Predictive Diagnostic Model for IgA Vasculitis Based on a Metabolomic Approach
Alexandre Boissais¹, Hélène Blasco², Patrick Emond³, Antoine Lefevre², Adrien Bigot⁴, denis Mulleman⁵, François Maillot⁴ and Alexandra Audemard-Verger⁴, ¹Medical University of Tours, Tours, France, ²Biochemistry and Molecular Biology Department, Tours, France, ³In vitro Nuclear Medicine Department, Tours, France, ⁴Department of Internal Medicine, Tours, France, ⁵Rheumatology Department, Tours, France
Background/Purpose: IgA vasculitis is a rare systemic disease that is life-threatening mainly due to digestive or renal involvement. To date, there is no reliable diagnostic…
Abstract Number: L16 • ACR Convergence 2021
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository
Jasvinder Singh¹, Namrata Singh², Alfred Anzalone³, Amy Olex⁴, Jing Sun⁵, Vithal Madhira⁶ and Rena Patel⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Washington, Bellevue, WA, ³University of Nebraska, Omaha, NE, ⁴Virginia Commonwealth University, Richmond, VA, ⁵Johns Hopkins University, Baltimore, MD, ⁶Palila Software, Reno, NV, ⁷Unviersity of Washington, Seattle, WA
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination…
Abstract Number: L01 • ACR Convergence 2021
Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full Vaccination in Patients with Inflammatory Rheumatic Diseases
Catherine Raptis¹, Diego Andrey², Christoph Berger³, Axel Finckh², Pierre Lescuyer², Adrian Ciurea⁴, Tanja Maletic¹, Christos Polysopoulos¹, Myriam Riek¹, Almut Scherer¹, Kim Lauper², Burkhard Moeller⁵, Judith Safford⁶, Sandra Schweizer⁷, Isabell von Loga¹, Nicolas Vuilleumier⁸ and Andrea Rubbert-Roth⁹, ¹SCQM Foundation, Zurich, Switzerland, ²Geneva University Hospital, Geneva, Switzerland, ³University Hospital Basel, Basel, Switzerland, ⁴University Hospital Zurich, Zrich, Switzerland, ⁵Inselspital - University Hospital Bern, Bern, Switzerland, ⁶RheumaCura Foundation, Zurich, Switzerland, ⁷Swiss League Against Rheumatism, Zurich, Switzerland, ⁸University Hospital of Geneva, Geneva, Switzerland, ⁹Kantonspital St Gallen, St.Gallen, Switzerland
Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy- following vaccination with mRNA COVID-19 vaccines but long-term data…
Abstract Number: L17 • ACR Convergence 2021
Additional Heterologous versus Homologous Booster Vaccination in Immunosuppressed Patients Without SARS-CoV-2 Antibody Seroconversion After Primary mRNA Vaccination: A Randomized Controlled Trial
Michael Bonelli¹, Daniel Mrak¹, Selma Tobudic¹, Daniela sieghart¹, Peter Mandl¹, barbara kornek¹, elisabeth simader¹, Maximilian Koblischke¹, Helga Radner¹, thomas perkmann¹, helmuth haslacher¹, Margareta Mayer¹, philipp hofer¹, Kurt Redlich², Emma Husar-Memmer³, Ruth Fritsch-Stork⁴, Renate Thalhammer¹, Karin Stiasny¹, Stefan Winkler¹, Josef Smolen¹, Judith Aberle¹, Markus Zeitlinger¹, Leonhard Heinz¹ and Daniel Aletaha⁵, ¹Medical University of Vienna, Vienna, Austria, ²Hietzing Hospital, Vienna, Austria, ³Hanusch Hospital, Vienna, Austria, ⁴Sigmund Freud University, Utrecht, Netherlands, ⁵Medical University Vienna, Wien, Austria
Background/Purpose: Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)-induced coronavirus disease 2019 (COVID-19) has led to exponentially rising mortality, particularly in immunosuppressed patients, who inadequately respond to…
Abstract Number: L02 • ACR Convergence 2021
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases
Ines Colmegna¹, Mariana Useche¹, Emmanouil Rampakakis², Nathalie Amiable³, Emmanuelle Rollet-Labelle³, Louis Bessette⁴, Jo-Anne Costa⁴, Marc Dionne⁴, Mary-Ann Fitzcharles², Elizabeth Hazel², Deirdre McCormack², Laetitia Michou⁴, Pantelis Panopalis², Marc-Andre Langlois⁵, Sasha Bernatsky⁶ and Paul R. Fortin⁷, ¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Centre de Recherche du CHU de Quebec, Quebec, Canada, ⁴Universite Laval, Quebec, QC, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷CHU de Quebec - Universite Laval, Quebec, Canada
Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…
Abstract Number: L18 • ACR Convergence 2021
Humoral and Cellular Immune Responses to a Second Dose of COVID-19 Vaccine BNT162b2 in People Receiving Methotrexate or Targeted Immunosuppression: A Cohort Study
Satveer K Mahil¹, Katie Bechman², Antony Raharja¹, Clara Domingo-Vila³, David Baudry¹, Matt Brown², Andrew Cope², Tejus Dasandi¹, Hataf Khan⁴, Thomas Lechmere⁴, Michael Malim⁴, Freya Meynell¹, Emily Pollock³, Kamila Sychowska³, Jonathan Barker¹, Sam Norton⁵, James Galloway², Katie Doores⁴, Timothy Tree³ and Catherine Smith¹, ¹St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, ²Centre for Rheumatic Diseases, King's College London, London, ³Department of Immunobiology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom, ⁴Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom, ⁵Psychology Department, Institute for Psychiatry Psychology & Neuroscience, King’s College London, London
Background/Purpose: COVID-19 vaccines have robust immunogenicity in the general population. Data on individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains limited. Our cohort…
Abstract Number: L03 • ACR Convergence 2021
COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents Depend on B-Cell Counts at Time of Vaccine
Kyriakos Kirou and Jeffrey Zhang-Sun, Hospital for Special Surgery, New York, NY
Background/Purpose: Optimal COVID-19 vaccine responses are necessary to protect against severe infection. Patients with systemic rheumatic diseases (SRD) are at risk for not mounting adequate…
Abstract Number: L19 • ACR Convergence 2021
Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial
Nils Venhoff¹, Wolfgang Schmidt², Raoul Bergner³, Jürgen Rech⁴, Leonore Unger⁵, Hans-Peter Tony⁶, Meryl Mendelson⁷, Christian Sieder⁸, Meron Maricos⁸ and Jens Thiel⁹, ¹Department of Rheumatology and Clinical Immunology, Vasculitis Center Freiburg, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany, ²Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Lindenberger Weg 19, 13125 Berlin, Germany, Berlin, Germany, ³Medizinische Klinik A, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany, ⁴Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054,, Erlangen, Germany, ⁵Medical Department 1, Städtisches Klinikum Dresden, Dresden, Germany, ⁶Department of Medicine 2, Rheumatology and Clinical Immunology Oberduerrbachertstr. 697080, Wuerzburg, Germany, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma GmbH, Nuremberg, Germany, ⁹Department of Rheumatology and Clinical Immunology, Vasculitis Center Freiburg, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany; Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Background/Purpose: Little is known about glucocorticoid-sparing agents in giant cell arteritis (GCA) except for IL-6 inhibition. Secukinumab (SEC) has shown significant improvements in the signs…
Abstract Number: L04 • ACR Convergence 2021
SARS-CoV-2 Infections Among Vaccinated Individuals with Rheumatic Disease: Results from the COVID-19 Global Rheumatology Alliance Provider Registry
Jean Liew¹, milena Gianfrancesco², Carly Harrison³, zara Izadi², Stephanie Rush², Lindsay Jacobsohn², Clairissa Ja², Saskia Lawson-Tovey⁴, Kimme Hyrich⁵, Laure Gossec⁶, Anja Strangfeld⁷, Loreto Carmona⁸, Martin Schaefer⁷, ELSA MATEUS⁹, Samar Al Emadi¹⁰, Claire Cook¹¹, Fatemah Abutiban¹², Dfiza Dey¹³, Emily Kowalski¹⁴, Marco Martinez-Martinez¹⁵, Naomi Patel¹¹, Evelyn Salido¹⁶, Jeffrey Sparks¹⁷, leanna Wise¹⁸, Suleman Bhana¹⁹, Wendy Costello²⁰, Rebecca Grainger²¹, Jonathan Hausmann²², Emily Sirotich²³, Paul Sufka²⁴, Zachary Wallace²⁵, Pedro Machado²⁶, Philip Robinson²⁷ and Jinoos Yazdany², ¹Boston University School of Medicine, Boston, MA, ²University of California San Francisco, San Francisco, CA, ³Lupus Chat, New York, NY, ⁴Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Sorbonne Universite, Paris, France APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France, Paris, France, ⁷German Rheumatism Research Center (DRFZ Berlin), Epidemiology and Health Care Research, Berlin, Germany, ⁸Instituto de Salud Musculoesquelética, Madrid, Spain, ⁹EULAR, Lisboa, Portugal, ¹⁰Hamad Medical Corporation, Doha, Qatar, ¹¹Massachusetts General Hospital, Boston, MA, ¹²Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah Hospital, KUWAIT, Kuwait, ¹³Rheumatology Unit , Department of Medicine and Therapeutics, University of Ghana Medical School, Korle Bu Teaching Hospital, Accra, Ghana, ¹⁴Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁵Instituto Mexicano del Seguro Social, San Luis Potosí, Mexico, ¹⁶University of the Philippines Manila, Manila, Philippines, ¹⁷Brigham and Women's Hospital, Boston, MA, ¹⁸University of Southern California, Los Angeles, CA, ¹⁹Pfizer, Montvale, NJ, ²⁰Irish Children's Arthritis Network (iCAN), Bansha, Ireland, ²¹University of Otago, Wellington, New Zealand, ²²Boston Childrens Hospital, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²³McMaster University, Hamilton, ON, Canada, ²⁴HealthPartners, Eagan, MN, ²⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²⁶Centre for Rheumatology & Department of Neuromuscular Diseases, University College London; National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust; Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom, ²⁷University of Queensland School of Clinical Medicine, Herston, Queensland; Department of Rheumatology, Royal Brisbane and Women’s Hospital, Metro North Hospital and Health Service, Queensland, Australia., Brisbane, Australia
Background/Purpose: While COVID-19 vaccinations are a critical tool to prevent severe infections, poor immunogenicity in immunocompromised people threatens vaccine effectiveness. We analyzed clinical characteristics of…
Abstract Number: L20 • ACR Convergence 2021
Efficacy of Emapalumab, an Anti-IFNγ Antibody in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA) Who Had Failed High-Dose Glucocorticoids (GCs)
Fabrizio De Benedetti¹, Alexei Grom², Paul Brogan³, Claudia Bracaglia¹, Manuela Pardeo¹, Giulia Marucci¹, Despina Eleftheriou³, Charalampia Papadopoulou³, Pierre Quartier⁴, Jordi Antón⁵, Rikke Frederiksen⁶, Veronica Asnaghi⁶ and Cristina De Min⁶, ¹Bambino Gesù Children's Hospital IRCCS, Rome, Italy, ²Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, ³UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁴Université de Paris, IMAGINE Institute, RAISE reference centre, Pediatric Immuno-Hematology and Rheumatology Unit, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁵Hospital Sant Joan de Déu, Division of Pediatric Rheumatology, University of Barcelona, Barcelona, Spain, ⁶Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland
Background/Purpose: MAS is a life-threatening complication of rheumatic diseases, occurring most frequently in sJIA. The mainstay of MAS treatment is high dose GCs; however, GCs…
Abstract Number: L05 • ACR Convergence 2021
Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy and Safety of Tigulixostat, a Novel Non-purine Selective Xanthine Oxidase Inhibitor, in Gout Patients with Hyperuricemia
Robert Terkeltaub¹, JuneSik Mune², Jieun Lee³ and Kenneth Saag⁴, ¹VA/UCSD, San Diego, CA, ²LG Chem, Ltd., Seoul, ³LG Chem, Ltd., Seoul, South Korea, ⁴The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout can be effectively managed by inhibiting synthesis of uric acid. Tigulixostat is a novel non-purine selective xanthine oxidase inhibitor which lowers production of…
Abstract Number: L21 • ACR Convergence 2021
Rituximab versus Conventional Therapeutic Strategy for Remission Induction in Eosinophilic Granulomatosis with Polyangiitis: A Double-blind, Randomized, Controlled Trial
Benjamin Terrier¹, Gregory Pugnet², Claire de Moreuil³, Bernard Bonnotte⁴, Ygal Benhamou⁵, Elisabeth Diot⁶, Dominique Chauveau², Pierre Duffau⁷, Nicolas Limal⁸, Antoine Neel⁹, Geoffrey Urbanski¹⁰, Noemie Jourde-Chiche¹¹, Nicolas Martin-Silva¹², Francois Maurier¹³, Arsene Mekinian¹⁴, Nicolas Schleinitz¹¹, Felix Ackermann¹⁵, Anne-Laure Fauchais¹⁶, Antoine Froissart¹⁷, Thomas Le Gallou¹⁸, Yurdagul Uzunhan¹⁹, Jean-Francois Viallard⁷, Alice Berezne²⁰, Laurent Chiche²¹, Bruno Crestani¹⁴, Guillaume Direz²², Cecile-Audrey Durel²³, Pascal Godmer²⁴, Jean-Emmanuel Kahn²⁵, Marc Lambert²⁶, Thomas Quemeneur²⁷, Jacques Cadranel¹⁴, Pierre Charles²⁸, Antoine Dossier¹⁴, Lea Jilet²⁹, Loic Guillevin¹⁴, Hendy Abdoul²⁹ and Xavier Puechal¹⁴, ¹Cochin Hospital, Paris, France, ²CHU, Toulouse, France, ³CHU, Brest, France, ⁴CHU, Dijon, France, ⁵CHU, Rouen, France, ⁶CHU, Tours, France, ⁷CHU, Bordeaux, France, ⁸CHU, Creteil, France, ⁹CHU, Nantes, France, ¹⁰CHU, Angers, France, ¹¹CHU, Marseille, France, ¹²CHU, Caen, France, ¹³CH, Metz, France, ¹⁴CHU, Paris, France, ¹⁵Hopital Foch, Suresnes, France, ¹⁶CHU, Limoges, France, ¹⁷CHIC, Creteil, France, ¹⁸CHU, Rennes, France, ¹⁹CHU, Bobigny, France, ²⁰CH, Annecy, France, ²¹CH, Marseille, France, ²²CH, Le Mans, France, ²³CHU, Lyon, France, ²⁴CH, Vannes, France, ²⁵CHU, Boulogne, France, ²⁶CHRU, Lille, France, ²⁷CH, Valenciennes, France, ²⁸CH, Paris, France, ²⁹URC, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic ANCA-associated vasculitis.Glucocorticoids, alone or in combination with cyclophosphamide in severe forms, induce remission in most patients…
Abstract Number: L06 • ACR Convergence 2021
Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach
Kazuki Yoshida, Jun Liu, Daniel Solomon, Robert J Glynn and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatology societies recommend serum-urate (SU)-driven treat-to-target (TTT) strategies for the management of gout. However, cardiovascular (CV) safety of urate-lowering therapy (ULT) has been questioned.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].